Diligence memo · auto-generated · as of July 2, 2026

Adze Biotechnology Inc

Adze Biotechnology Inc looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Adze Biotechnology Inc operates in Biotechnology, based in CORAL GABLES.

Sub-sector tags: biotech.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Adze Biotechnology Inc has raised $9.8M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.2M on 2023-03-10.

Most recent recorded round closed around 2023-03-10.

Valuation (modeled)modeled

Provath models Adze Biotechnology Inc at approximately $61M (range $6.7M–$178M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.37× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Within the normal band (137% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 5 months.

Last raise 3.3 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round was 1.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 56% of Biotechnology peers (4293 compared).

Modeled value ranks above 49% of those peers.

Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..

Peoplefiled

11 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.